LIfT BioSciences Archives

Home LIfT BioSciences

Latest Posts

News and Trends 6 Jul 2023

LIfT produces neutrophil-based cell therapy from iPSCs

LIfT BioSciences has announced successful proof-of-concept production of its patented cancer-killing alpha neutrophils from induced pluripotent stem cells (iPSCs). The proof-of-concept using iN-LIfT, the company’s second-generation platform, which is derived from iPSCs (a type of cell that has been reprogrammed so it is capable of becoming any type of cell) has shown that the alpha […]

July 6, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 4 May 2023

LIfT BioSciences says data show potent killing of pancreatic cancer tumoroids

LIfT BioSciences has revealed preclinical data demonstrating that its immunomodulatory alpha neutrophil product (IMAN) showed potent killing of pancreatic cancer tumoroids. The tumoroid originated from a patient with pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer. The patient was unresponsive to conventional chemotherapy treatment with Abraxane (nab-paclitaxel), but initially responded positively to […]

May 4, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 23 Mar 2023

LIfT BioSciences hails breakthrough data for treating solid tumors

LIfT BioSciences has announced what it says are exciting preclinical data demonstrating that its immunomodulatory alpha neutrophil product (IMANp) possesses both cytotoxic and immunomodulatory functionalities. The company said these are commonly cited by medical professionals as being critical for potentially curing solid tumors in patients. LIfT BioSciences said this involved learning from the experience of other […]

March 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 19 Dec 2022

LIfT BioSciences gets a double boost

LIfT BioSciences’ is receiving more investment, and has been accepted into Johnson & Johnson Innovation’s JLABS network. LIfT BioSciences’ lead investor, Starbloom Capital, provided further investment into the company to accelerate LIfT’s R&D plans and progress N-LIfT, the company’s first-to-market anti-cancer innate cell therapy, (neutrophil only leukocyte infusion therapy) into clinical development by Q1 2024, […]

December 19, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 14 Sep 2022

Tumors destroyed in five types of cancer by cell therapy from LIfT BioSciences

LIfT BioSciences announced today (September 14) that its cell therapy has shown tumor destruction across five different solid tumor types in tumoroid models. The N-LIfT cell therapy destroyed on average more than 90% of the tumoroid in a PDX organoid across five of the most challenging to treat solid tumor types. A PDX organoid is […]

September 14, 2022 - 4 minutesmins - By Liza Laws

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us